PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Shining a Light on the Treatment of Primary Hyperoxaluria 1: Does the Evidence Improve Our Options?
Visit https://www.peervoice.com/QYZ860 to view the entire programme with slides. After completing “Shining a Light on the Treatment of Primary Hyperoxaluria 1: Does the Evidence Improve Our Options?”, participants will be able to: Summarise key findings from published studies evaluating RNA interference (RNAi) targeting glycolate oxidase in patients with primary hyperoxaluria type 1 (PH1); Discuss the strengths and limitations of these studies in light of current practices for the management of PH1; Describe the impact of these data on clinical practice within the context of current and future treatment paradigms for PH1.